National Cancer Center and HITS Collaborate on AI-Based Anticancer Drug Development
Accelerating Anticancer Drug Development
with a Dedicated AI Drug Development Platform
The National Cancer Center Research Institute announced on June 23 that it has signed a Memorandum of Understanding (MOU) with HITS Co., Ltd., a company specializing in AI-based drug development platforms, for the establishment of an AI-based anticancer drug development platform and research collaboration.
Eo Geon-guk, Director of the National Cancer Center Research Institute (5th from the left), and Woo-yeon Kim, CEO of HITS Inc. (4th), are posing for a commemorative photo after signing a memorandum of understanding (MOU) on the 18th for the establishment of an AI-based anticancer drug development platform and research cooperation. National Cancer Center
View original imageThis agreement was established to enhance the efficiency of the AI-based anticancer drug development research being conducted by the National Cancer Center, and to strengthen the foundation for the discovery and optimization of anticancer drug candidates by linking the National Cancer Center's cancer research capabilities with the AI drug development platform technology of HITS.
Under the agreement, the two organizations plan to cooperate in various areas, including: building and operating an AI-based drug development platform dedicated to the National Cancer Center; reviewing the use of research support tools such as AI-based candidate compound design, virtual screening, and predictive analysis; discussing the application possibilities of omics analysis and anticancer drug development-related functions; and exploring research utilization strategies for the platform and subsequent collaboration models.
The National Cancer Center Research Institute is currently conducting research to build and validate a dedicated AI-based anticancer drug development platform using AI technology. The goal is to implement a closed-loop drug development system where AI-driven molecular design and prediction, synthesis and experimental validation, and retraining using experimental data are carried out in a continuous cycle. This approach is expected to reduce the time and cost required in conventional drug development processes, and to improve the efficiency of discovering and optimizing new candidate compounds by building and integrating customized AI models specialized for various modalities of anticancer drug development.
HITS possesses technologies for predicting protein-ligand binding, structure-based virtual screening, generative molecular design, and drug-likeness and toxicity prediction. Based on these technologies and research capabilities, the two organizations plan to gradually advance the AI-powered research environment necessary for anticancer drug development.
In particular, this agreement goes beyond simply introducing a platform; it aims to create a research collaboration model for anticancer drug development that reflects actual medical field needs by combining the National Cancer Center's competencies in structural biology, omics, drug screening, and preclinical research with AI technology. Moving forward, the institutions plan to continuously improve the AI-based candidate compound design and verification system based on feedback from the research field, thereby increasing the likelihood of generating tangible research outcomes and successful drug development.
Geon-Kuk Lee, Director of the National Cancer Center Research Institute, stated, "Effectively linking the research capabilities and data possessed by the National Cancer Center with AI technology is an important direction for future anticancer drug development research. With this agreement, we will establish a dedicated AI drug development platform for the National Cancer Center and connect the needs of research sites with the technology of specialized companies to produce practical research outcomes."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Woo-Yeon Kim, CEO of HITS, remarked, "To solve the complex challenges in the medical and bio fields, we need expertise from various disciplines, outstanding technology, and deep feedback from field researchers. We hope that HITS's AI drug development technology will be meaningfully utilized in the National Cancer Center's anticancer research field and contribute to the shared goal of overcoming cancer."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.